ArticleFrontiers in oncology2025
Ultrasound-based radiomics combined with B3GALT4 level to predict sentinel lymph node metastasis in primary breast cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the value of the clinical model for predicting axillary lymph node metastasis (ALNM) of breast cancer before operation by integrating ultrasound (US) and β-1,3-galactosyltransferase-4 (B3GALT4) expression level of the primary tumor. Methods: A total of 135 breast cancer patients who underwent US examination and axillary lymph nodes dissection (ALND) were enrolled. They were randomly divided into a training group (95 cases) and a verification group (40 cases). The ultrasound imaging characteristics of the primary tumor were extracted from each region of interest (ROI), and the Spearman correlation coefficient, least absolute shrinkage and selection operator (LASSO), and the minimum redundancy maximum relevance (mRMR) were used for feature selection. The radiomics model was constructed by eighteen machine-learning techniques. B3GALT4 expression level of the primary tumor was analyzed using quantitative real-time polymerase chain reaction (qRT-PCR). A clinical model was constructed based on B3GALT4 mRNA level. Further, a nomogram was established by integrating B3GALT4 and the radiomics signature. The effectiveness of each model was evaluated by receiver operating characteristic (ROC) curve, Hosmer-Lemeshow test, calibration curve, and decision curve analyses (DCA). Results: A total of 1562 radiomics features were extracted, and 30 features were selected. The SVM model had the highest AUC values of 0.937 and 0.932 in the training and validation sets. The AUC of the radiomics model was 0.937 (95% CI: 0.885-0.989) in the training cohort and 0.932 (95% CI: 0.860-1.000) in the external validation cohort, respectively. The levels of B3GALT4 mRNA were significantly different between the ALNM and non-ALNM groups (P<0.001). The clinical model achieved a higher AUC (training group, 0.904; validation group, 0.887). The nomogram performed well in both the training set (AUC = 0.991) and the validation set (AUC = 0.975). The nomogram had satisfactory clinical utility. Conclusion: The nomogram constructed by ultrasound features and B3GALT4 of the primary tumor can be used as an effective tool for individualized prediction of ALNM in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.